Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity

NCT02849418 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02849418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02849418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
October 11, 2016
Completion date
December 20, 2018
Enrollment
21 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder, overactive